Videos

Herbert Bravo, MD, and Marian Rewers, MD, PhD, explain how education and coordinated care are key to implementing early screening and treatment for type 1 diabetes.

A peer-to-peer discussion between Herbert Bravo, MD; and Marian Rewers, MD, PhD, examined immune-based treatments that preserved β-cell function and altered disease progression.

Herbert Bravo, MD, and Marian Rewers, MD, PhD, explored how C-peptide preservation reshaped both clinical management and economic considerations in type 1 diabetes.

Clinicians reviewed evidence linking delayed diagnosis of type 1 diabetes to lasting neurologic and metabolic consequences.

Experts discussed how the 3-stage model reframed type 1 diabetes as a condition that could be detected through earlier screening.

This introductory Special Report episode outlines how advances in staging and early detection are reshaping pediatric approaches to type 1 diabetes.

Jonathan Flyer, MD, discusses how the LEAD Pediatric Initiative is addressing persistently low rates of universal pediatric lipid screening.

GeneDx’s ExomeDx and GenomeDx tests, now FDA Breakthrough Designated, offer comprehensive genomic analysis to improve diagnosis of rare and serious diseases.

“Having a drug that [patients] can be confident in that will be highly effective as well as well tolerated is a great advantage," said Edward Hook, MD.

Clinicians now have the first oral alternative to injectable therapy for gonorrhea, a shift Angela Hasler, APRN, CPNP-PC says could ease treatment barriers and improve public health outcomes.

Following an updated policy from the American Academy of Child and Adolescent Psychiatry, Joshua Feder, MD, explains why providers should present DRBIs and NDBIs as options for autism care.

Researchers report that cheek swabs can capture early microscopic changes of ACM, offering a noninvasive path to earlier diagnosis and intervention.

Christine Eng, MD, discusses how earlier genome testing, multi-omic tools, rapid sequencing, and improved access can shorten diagnostic timelines and guide care.

Christine Eng, MD, discusses insurance, access, logistics, and result interpretation challenges affecting effective use of exome and genome sequencing.

New AAP guidance supports early use of exome and genome sequencing, offering higher diagnostic yield and faster results for children with developmental delay and ID.

Joshua Feder, MD, highlights how interest-based, blended, and ABA strategies can all be effective options when working with a child with autism.

Joshua Feder, MD, explains how AACAP’s revised policy aims to improve access, insurance coverage, and family-centered decision-making for autism care.

Alice Hoyt, MD, FAAAI, underscored three core recommendations for improving pediatric food allergy management, emphasizing coordinated care and reliable access to epinephrine.

Jonathan Flyer, MD, emphasizes that early detection of FH through guideline-recommended universal screening can be lifesaving and supports broader family identification.

Jonathan Flyer, MD, highlights strategies to improve universal pediatric lipid screening and early detection of familial hypercholesterolemia in children.

Findings from a pilot randomized trial of a multifaceted pediatric obesity care model found strong family engagement and highlighted the importance of psychosocial support in treatment.

Druhan Howell highlighted that pediatric patients using tapinarof cream experienced rapid symptom relief and improved quality-of-life measures, with no new safety concerns.

Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.

Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

George Rodgers, III, MD, PhD, emphasized that antithrombin III’s expanded pediatric label provides "a sterile, plasma-derived product that will specifically correct the deficiency in a more safe fashion."

Alice Hoyt, MD, FAAAI, discussed the Early Childhood Anaphylaxis Collaborative’s efforts to improve anaphylaxis preparedness in early childcare settings.

"What is the possibility for your individual child that you're taking care of as a patient, as a family member advocate?" said Oliva Kim-McManus, MD.

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Panelists discuss how low systemic absorption and simple dosing schedules improve safety, adherence, and caregiver confidence in pediatric AD care.